Titlebook: New Therapeutic Targets in Rheumatoid Arthritis; Paul-Peter Tak Book 2009 Birkh?user Basel 2009 Arthritis.Chemokine.Drug Target.Interleuki

鋪子

Perspectives in targeted therapy,ombination with methotrexate, use in moderate rather than severe disease, tight control as well as induration and maintenance regimes. Despite therapeutic advances with target therapies a number of unmet needs exist, including a low remission rate, cost and inadequate access as well as the lack of b

金絲雀

Book 2009 inflammatory diseases. Anti-TNF treatment results in cli- cal benefit in a significant proportion of the patients, and it has provided proof of concept for the principle of targeted therapy. Despite the impressive disease-modifying effects of the TNF blockers, not all patients respond, and patients

黃瓜

1422-7746 oportion of the patients, and it has provided proof of concept for the principle of targeted therapy. Despite the impressive disease-modifying effects of the TNF blockers, not all patients respond, and patients978-3-7643-8238-4Series ISSN 1422-7746 Series E-ISSN 2296-4525

jettison

palpitate

Albumin

chapel

Entreaty

有特色

B cell targets in rheumatoid arthritis,atients with RA using the first licensed agent, rituximab. Recent research has focused on enhancing efficacy using other targets to inhibit B cell function, including other B cell-depleting antibodies and cytokines critical to B cell function. The rationale for new B cell targets is discussed, as we

Isolate

Co-stimulatory pathways in the therapy of rheumatoid arthritis, cell populations have not been clinically successful, largely due to the toxicity associated with nonspecific T cell depletion. An alternative approach involves targeting T cell activation, a process that requires two distinct signals. In addition to the cognate interaction between the T cell recep